Variable | Not alive or not at home 1 year after surgery OR (95% CI) | Lung-cancer-specific mortality HR (95% CI) | Non-cancer-specific mortality HR (95% CI) | Overall mortality HR (95% CI) |
Stair climbing <11 m versus >12 m, adjusted# | 3.82 (1.28–11.4) | 1.25 (0.55–2.85) | 4.28 (2.10–8.73) | 2.38 (1.43–3.98) |
Age at surgery >80 years versus <80 years, adjusted# | 9.82 (2.31–41.8) | 1.08 (0.28–4.11) | 3.38 (1.20–9.48) | 1.97 (0.89–4.35) |
Male sex versus female, adjusted# | 0.54 (0.18–1.66) | 1.11 (0.51–2.43) | 2.86 (1.27–6.45) | 1.76 (1.01–3.07) |
Former smoker versus never, adjusted# | NA | 1.99 (0.53–7.50) | 1.73 (0.61–4.87) | 1.82 (0.82–4.06) |
Current smoker versus never, adjusted# | NA | 2.21 (0.56–8.78) | 1.43 (0.50–4.12) | 1.65 (0.72–3.81) |
Charlson comorbidity index ≥5 versus <5 points, adjusted# | 5.57 (1.38–22.6) | 2.90 (0.90–9.35) | 3.40 (1.21–9.54) | 2.79 (1.32–5.90) |
ppoFEV1 ≤50% versus >50%, adjusted# | 1.81 (0.55–5.98) | 0.86 (0.34–2.16) | 1.65 (0.70–3.87) | 1.14 (0.62–2.10) |
ppoDLCO ≤50% versus >50%, adjusted# | 4.33 (1.27–14.8) | 0.96 (0.37–2.48) | 1.81 (0.79–4.14) | 1.43 (0.78–2.63) |
Adenocarcinoma versus squamous cell cancer, adjusted# | 1.35 (0.41–4.47) | 1.54 (0.63–3.74) | 1.69 (0.78–3.67) | 1.50 (0.85–2.63) |
Stage II versus stage I, adjusted# | 2.50 (0.62–9.98) | 3.27 (1.23–8.68) | 1.27 (0.57–2.81) | 1.66 (0.92–3.02) |
Stage III versus stage I, adjusted# | 8.18 (1.53–43.7) | 5.75 (1.75–18.9) | 0.44 (0.08–2.31) | 2.04 (0.89–4.70) |
ppo: predicted post-operative; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide. #: adjustment for age, sex, tobacco use, Charlson comorbidity index, ppoFEV1, ppoDLCO, histological type, stage, neo- or adjuvant treatment, and stair-climbing group (<11 and >12 m). Statistically significant values are highlighted in bold.